Dr. Eric Orman, M.D

Student in an Organized Health Care Education/Training Program Indianapolis, IN Male
NPI: 1730208562
Total Payments
$70,877
2024 Payments
$64,737
Companies
2
Transactions
14
Medicare Patients
575
Medicare Billing
$61,738

Payment Breakdown by Category

Research$70,787 (99.9%)
Food & Beverage$90.35 (0.1%)

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $70,787 13 99.9%
Food and Beverage $90.35 1 0.1%

Payments by Type

Research
$70,787
13 transactions
General
$90.35
1 transactions

Top Paying Companies

Company Total Records Latest Year
Bausch Health US, LLC $70,787 13 $0 (2024)
Cumberland Pharmaceuticals, Inc. $90.35 1 $0 (2017)

Payment History by Year

Year Amount Transactions Top Company
2024 $64,737 9 Bausch Health US, LLC ($64,737)
2023 $6,050 4 Bausch Health US, LLC ($6,050)
2017 $90.35 1 Cumberland Pharmaceuticals, Inc. ($90.35)

All Payment Transactions

14 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
11/22/2024 Bausch Health US, LLC XIFAXAN (Drug) — Cash or cash equivalent $4,700.00 Research
Study: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis • Category: Gastroenterology
10/25/2024 Bausch Health US, LLC XIFAXAN (Drug) — Cash or cash equivalent $6,000.00 Research
Study: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis • Category: Gastroenterology
10/04/2024 Bausch Health US, LLC XIFAXAN (Drug) — Cash or cash equivalent $6,000.00 Research
Study: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis • Category: Gastroenterology
09/01/2024 Bausch Health US, LLC XIFAXAN (Drug) — Cash or cash equivalent $3,200.00 Research
Study: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis • Category: Gastroenterology
07/01/2024 Bausch Health US, LLC XIFAXAN (Drug) — Cash or cash equivalent $2,500.00 Research
Study: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis • Category: Gastroenterology
06/18/2024 Bausch Health US, LLC XIFAXAN (Drug) — Cash or cash equivalent $3,000.00 Research
Study: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis • Category: Gastroenterology
04/19/2024 Bausch Health US, LLC XIFAXAN (Drug) — Cash or cash equivalent $4,336.96 Research
Study: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis • Category: Gastroenterology
02/29/2024 Bausch Health US, LLC XIFAXAN (Drug) — Cash or cash equivalent $2,500.00 Research
Study: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis • Category: Gastroenterology
02/02/2024 Bausch Health US, LLC XIFAXAN (Drug) — Cash or cash equivalent $32,500.00 Research
Study: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis • Category: Gastroenterology
12/22/2023 Bausch Health US, LLC XIFAXAN (Drug) — Cash or cash equivalent $3,000.00 Research
Study: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis • Category: Gastroenterology
11/20/2023 Bausch Health US, LLC XIFAXAN (Drug) — Cash or cash equivalent $1,500.00 Research
Study: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis • Category: Gastroenterology
02/17/2023 Bausch Health US, LLC XIFAXAN (Drug) — Cash or cash equivalent $500.00 Research
Study: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis • Category: Gastroenterology
01/23/2023 Bausch Health US, LLC XIFAXAN (Drug) — Cash or cash equivalent $1,050.00 Research
Study: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis • Category: Gastroenterology
10/21/2017 Cumberland Pharmaceuticals, Inc. — Food and Beverage In-kind items and services $90.35 General

Research Studies & Clinical Trials

Study Name Company Amount Records
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis Bausch Health US, LLC $70,787 13

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 8 210 305 $86,840 $24,623
2022 8 155 206 $68,555 $15,535
2021 5 104 132 $45,026 $10,899
2020 4 106 165 $32,577 $10,682
Total Patients
575
Total Services
808
Medicare Billing
$61,738
Procedure Codes
27

All Medicare Procedures & Services

27 procedure records from CMS Medicare Utilization — Page 1 of 2

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes Facility 2023 28 107 $16,264 $6,314 38.8%
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes Facility 2023 35 38 $16,036 $4,918 30.7%
45385 Removal of polyps or growths of large bowel using an endoscope with mechanical snare Facility 2023 18 18 $22,626 $3,356 14.8%
99213 Established patient office or other outpatient visit, 20-29 minutes Facility 2023 39 46 $7,176 $2,017 28.1%
99204 New patient office or other outpatient visit, 45-59 minutes Office 2023 14 14 $4,382 $1,477 33.7%
99204 New patient office or other outpatient visit, 45-59 minutes Facility 2023 17 17 $5,321 $1,442 27.1%
99205 New patient office or other outpatient visit, 60-74 minutes Facility 2023 11 11 $4,466 $1,342 30.0%
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2023 19 19 $4,104 $1,281 31.2%
99239 Hospital discharge day management, more than 30 minutes Facility 2023 13 15 $3,345 $1,277 38.2%
99213 Established patient office or other outpatient visit, 20-29 minutes Office 2023 16 20 $3,120 $1,198 38.4%
45385 Removal of polyps or growths of large bowel using an endoscope with mechanical snare Facility 2022 18 18 $22,626 $3,269 14.4%
99232 Follow-up hospital inpatient care per day, typically 25 minutes Facility 2022 19 57 $8,664 $3,039 35.1%
99205 New patient office or other outpatient visit, 60-74 minutes Facility 2022 19 19 $7,714 $2,331 30.2%
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2022 30 35 $7,560 $2,213 29.3%
99213 Established patient office or other outpatient visit, 20-29 minutes Facility 2022 33 39 $6,084 $1,798 29.6%
99239 Hospital discharge day management, more than 30 minutes Facility 2022 12 14 $3,122 $1,034 33.1%
99215 Established patient office or other outpatient visit, 40-54 minutes Facility 2022 13 13 $3,809 $975.94 25.6%
43239 Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope Facility 2022 11 11 $8,976 $875.38 9.8%
45385 Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare Facility 2021 16 16 $20,426 $3,085 15.1%
99223 Initial hospital inpatient care, typically 70 minutes per day Facility 2021 20 20 $8,440 $2,750 32.6%
99232 Subsequent hospital inpatient care, typically 25 minutes per day Facility 2021 13 34 $5,168 $1,850 35.8%
99213 Established patient outpatient visit, total time 20-29 minutes Facility 2021 35 40 $6,240 $1,769 28.3%
99214 Established patient outpatient visit, total time 30-39 minutes Facility 2021 20 22 $4,752 $1,444 30.4%
99232 Subsequent hospital inpatient care, typically 25 minutes per day Facility 2020 24 71 $10,792 $3,972 36.8%
99223 Initial hospital inpatient care, typically 70 minutes per day Facility 2020 23 24 $10,128 $3,743 37.0%
12»

About Dr. Eric Orman, M.D

Dr. Eric Orman, M.D is a Student in an Organized Health Care Education/Training Program healthcare provider based in Indianapolis, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/29/2007. The National Provider Identifier (NPI) number assigned to this provider is 1730208562.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Orman, M.D has received a total of $70,877 in payments from pharmaceutical and medical device companies, with $64,737 received in 2024. These payments were reported across 14 transactions from 2 companies. The most common payment nature is "" ($70,787).

As a Medicare-enrolled provider, Orman has provided services to 575 Medicare beneficiaries, totaling 808 services with total Medicare billing of $61,738. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.

Practice Information

Products in Payments

  • XIFAXAN (Drug) $70,787

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Student in an Organized Health Care Education/Training Program Doctors in Indianapolis

Kevin Trulock, M.d, M.D

Student in an Organized Health Care Education/Training Program — Payments: $246,254

Student in an Organized Health Care Education/Training Program $246,254

Nikolajs Perdue, M.d, M.D

Student in an Organized Health Care Education/Training Program — Payments: $221,939

Student in an Organized Health Care Education/Training Program $221,939

Christopher Healy

Student in an Organized Health Care Education/Training Program — Payments: $113,924

Student in an Organized Health Care Education/Training Program $113,924

Dustin Holland, M.d., M.p.h, M.D., M.P.H

Student in an Organized Health Care Education/Training Program — Payments: $38,628

Student in an Organized Health Care Education/Training Program $38,628

Dr. Ashish Pulikal, M.d, M.D

Student in an Organized Health Care Education/Training Program — Payments: $34,359

Student in an Organized Health Care Education/Training Program $34,359

Robert Godley, Md, MD

Student in an Organized Health Care Education/Training Program — Payments: $27,915

Student in an Organized Health Care Education/Training Program $27,915